Insider Selling: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Sells $11,200.00 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Jill Henrich sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $11.20, for a total transaction of $11,200.00. Following the completion of the sale, the executive vice president now owns 19,378 shares of the company’s stock, valued at approximately $217,033.60. The trade was a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Atara Biotherapeutics Stock Performance

Shares of ATRA opened at $11.47 on Friday. Atara Biotherapeutics, Inc. has a one year low of $6.50 and a one year high of $39.50. The company has a 50-day simple moving average of $9.19 and a two-hundred day simple moving average of $10.11.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping the consensus estimate of ($3.77) by $0.84. The firm had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same period in the previous year, the company earned ($16.50) earnings per share. As a group, equities research analysts predict that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current year.

Hedge Funds Weigh In On Atara Biotherapeutics

Several large investors have recently made changes to their positions in ATRA. BNP Paribas Financial Markets increased its position in Atara Biotherapeutics by 29.3% during the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after buying an additional 86,842 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Atara Biotherapeutics by 49.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock worth $1,830,000 after purchasing an additional 873,133 shares during the last quarter. Delap Wealth Advisory LLC bought a new position in Atara Biotherapeutics in the 1st quarter worth about $29,000. Price T Rowe Associates Inc. MD raised its holdings in Atara Biotherapeutics by 8,916.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock worth $3,442,000 after buying an additional 4,903,159 shares during the last quarter. Finally, Redmile Group LLC increased its position in shares of Atara Biotherapeutics by 1.7% during the first quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock valued at $6,429,000 after acquiring an additional 156,863 shares in the last quarter. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ATRA. Canaccord Genuity Group upped their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Finally, Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and cut their target price for the stock from $25.00 to $18.00 in a report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, Atara Biotherapeutics currently has a consensus rating of “Hold” and an average price target of $16.67.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.